A landmark new FDA guidance makes patient preference data central to medical device approvals — reshaping how manufacturers think about benefit-risk decisions across the entire product life cycle.
Source: FDA Guidance Document, March, 2026 | CDRH & CBER
For decades, the question at the heart of medical device regulation has been a clinical one: does the device work, and is it safe? But a new FDA guidance published on March 30, 2026 signals a meaningful shift in how that question is answered — and who gets to weigh in.
The guidance, titled Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle, updates and substantially expands the agency’s 2016 framework on patient preference information (PPI). Its message is clear: the patients who live with a disease and use medical devices have perspectives on benefit and risk that regulators, clinicians, and device manufacturers cannot afford to ignore.
What Is Patient Preference Information — and Why Does It Matter?
Patient preference information is a specific type of patient experience data. The FDA defines it as qualitative or quantitative assessments of how desirable or acceptable patients find particular outcomes or attributes across different medical options. In plain terms: it captures what patients actually value and what tradeoffs they are genuinely willing to make.
This is distinct from a patient-reported outcome (PRO), which measures a patient’s self-assessed health status at a given point in time. A PRO might tell you how much pain a patient is in today. PPI tells you how much risk of a side effect a patient would accept in exchange for a specific reduction in that pain. The difference is one of measurement versus preference — and it’s the preference data that can directly inform whether a device should be approved, for whom, and under what conditions.
PPI is particularly useful when no clearly superior treatment option exists; when the clinical evidence is genuinely uncertain across patient groups; when patients and clinicians disagree on what constitutes acceptable risk; when key endpoints are inherently subjective; or when a device addresses a rare disease or unmet need where patients may have a significantly higher tolerance for risk.
From a One-Time Filing to a Lifelong Conversation
The 2016 guidance focused narrowly on PPI submitted alongside premarket approval applications (PMAs), humanitarian device exemptions (HDEs), and De Novo requests. The new guidance is considerably broader. The FDA now expects patient preference data to be relevant — and potentially considered — at every stage of a device’s existence.
In the earliest design and ideation phases, qualitative patient input can identify what device features actually matter to end users, helping manufacturers avoid building products that serve clinical endpoints but frustrate the patients who use them. As development moves into clinical trials, quantitative PPI can help define what counts as a meaningful benefit — a number that directly shapes the trial’s design, sample size calculations, and success criteria. And post-approval, as real-world data accumulates, patient preferences can drive labeling updates, indication expansions, and, where needed, redesigns.
The guidance also makes explicit that PPI is now relevant to 510(k) submissions, investigational device exemption (IDE) applications, Breakthrough Device designation requests, and even enforcement and administrative decisions — a significant broadening from the previous framework.
How the FDA Evaluates Patient Preference Studies
Voluntary submission does not mean uncritical acceptance. The guidance dedicates considerable space to the qualities that make a PPI study credible.
Study population. The study must genuinely reflect the full spectrum of patients for whom a device is intended. A small or unrepresentative sample makes results unreliable. Where preferences are expected to differ significantly between subgroups — by age, disease stage, or prior treatment experience — those subgroups need to be adequately enrolled and analyzed separately.
Communicating risk clearly. One of the most practically detailed sections addresses how to communicate probability to patients who may have limited health numeracy. The FDA recommends avoiding purely verbal risk descriptions (terms like “low” or “high” are interpreted inconsistently), steering clear of fractions and decimals, and where possible presenting both positive and negative framings of the same risk. Stating that a treatment carries a 20% chance of an adverse event alongside an 80% chance of no adverse event reduces cognitive bias and leads to more reliable preference data.
Avoiding cognitive bias. The guidance flags well-documented psychological pitfalls — framing effects, anchoring, and ordering effects — that can distort patient responses. A study that tells patients surgery has a 90% survival rate will systematically produce different results from one that presents the same procedure as carrying a 10% mortality rate, even though the two statements are mathematically identical. Robust study design minimizes these distortions through careful framing and internal validity checks.
Research standards. The FDA points to ISPOR (the Professional Society for Health Economics and Outcomes Research) as an example body whose good research practice guidelines PPI studies should follow. Adherence to such standards significantly strengthens the credibility of submitted data.
Real-World Cases: What This Looks Like in Practice
The guidance includes five illustrative scenarios showing how PPI can — and cannot — change a regulatory outcome.
A knee pain device showed modest benefit across its broad trial population, but PPI revealed that patients with the highest pain and functional limitation found the benefit clearly worthwhile given the risks. The FDA approved it — but only for that subgroup. PPI effectively carved out a viable indication from an otherwise failed broad application.
An aesthetic facial device produced improvement that faded over two years. Reviewers initially doubted whether this temporary effect was sufficient. PPI showed many patients actively preferred a resorbable, temporary device over a permanent implant. FDA approved it with appropriate labeling.
In a cautionary counterexample, patients expressed willingness to accept higher reoperation rates for a body-contouring device — but the FDA still declined approval, concluding the device posed unreasonable risk that design changes could address. Patient preference data informs decisions; it does not override safety standards.
A new hearing implant carried higher surgical risk than existing alternatives, with similar effectiveness — but patients strongly preferred its discrete, fully implantable profile. PPI was a key factor in the FDA’s approval determination. And for a novel pediatric heart valve device, a patient group submitted PPI from parents — the relevant decision-makers in that context — showing a majority preferred the new device’s long-term durability despite higher operative mortality. The FDA and its Advisory Committee weighed this favorably.
What This Means for Device Manufacturers
The most important practical shift embedded in this guidance is timing. The FDA repeatedly emphasizes that early engagement — before data collection begins, ideally at protocol development stage — is where sponsors gain the most. Waiting to think about PPI until a submission is being assembled is, by the guidance’s own logic, likely too late to produce data of genuine regulatory value.
The guidance recommends using the FDA’s Q-Submission program to seek feedback on study design, attribute selection, survey instruments, and sampling strategies. This iterative dialogue is positioned not as bureaucratic overhead but as a path to submissions that reviewers are far more likely to find meaningful.
Manufacturers with a comprehensive, longitudinal patient preference program — one that begins at design and continues through post-market monitoring — will be better positioned than those who treat PPI as a one-time box to tick.
The Broader Signal
Read in context, this guidance is part of a decade-long evolution in how the FDA thinks about regulatory evidence. The 21st Century Cures Act directed the agency to incorporate patient experience into the product development process. This guidance is the most comprehensive operationalization of that mandate in the device space to date.
For the medical device industry, the message is that patient centricity is no longer a values statement — it is increasingly a methodological requirement, with clear standards, documented good practices, and real consequences for approval decisions. For patients, it represents a meaningful, structured route for their lived experience to shape the regulatory decisions that govern their care.
